|Articles|January 1, 2001

January 2001
Volume 7
Issue 1

Ambulatory Drug Utilization Review: Opportunities for Improved Prescription Drug Use

Author(s)Alan Lyles, ScD, MPH, RPh, Betsy Sleath, PhD, RPh, Thomas R. Fulda

Download PDF: Ambulatory Drug Utilization Review: Opportunities for Improved Prescription Drug Use

Articles in this issue

over 25 years ago

Article

Indirect Cost of Ischemic Heart Disease to Employers

over 25 years ago

Article

Disenrollment from Medicare HMOs

over 25 years ago

Article

A Comparison of Abciximab Use in MCO and Non-MCO Populations

over 25 years ago

Article

Drugs and the Elderly, Part 2: Strategies for Improving Prescribing in a Managed Care Environment

over 25 years ago

Article

The Employer's Perspective

over 25 years ago

Article

Can Administrative Database Studies Inform Medication Use Policy Decisions? An Application of Occam's Razor

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Ambulatory Drug Utilization Review: Opportunities for Improved Prescription Drug Use

Articles in this issue

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

ACA Enrollment Erosion Deepens After Open Enrollment Ends

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

Efgartigimod Effective in Broad Subsets of Patients With gMG

Alopecia Areata Takes a Hidden Toll on Work, Relationships, and Self-Care